资源描述:
《低分子肝素钠治疗慢性阻塞性肺疾病急性加重期的疗效观察》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、低分子肝素钠治疗慢性阻塞性肺疾病急性加重期的疗效观黄春兰(成都市第五人民医院老年呼吸科四川成都610000)【摘要】R的:探讨低分子肝素钠在慢性阻塞性肺疾病急性加重期(AECOPD)屮的应用。方法:选择2011年1月〜2012年12月间我院老年呼吸科住院的100例慢性阻塞性肺疾病急性加重期患者,随机将其分为观察组和对照组,每组50例患者。本组100例性阻塞性肺疾病急性加重期患者全部采取常规治疗,必要时给予无创通气同时,还包括糖皮质激素、支气管扩张剂、有效抗生素、控制性氧疗等。观察组在此基础上在脐旁皮下注射低分子肝素钠,型号是6000U,连用十
2、天,每口一次。结果:经过治疗Z后,50例观察组患者显效40例(80%),好转9例(18%),无效1例(2%),总有效率98%。50例对照组患者显效30例(60%),好转8例(16%),无效12例(24%),总有效率76%。经应用x2检验(x2=424),两组之间的差异具有显著性(P<005)o对照组出现了6例不良反应,而治疗组只有2例患者在注射的过程屮出现了局部淤血外,没有出现其它不良反应。结论:慢性阻塞性肺疾病急性发作期加用低分子肝素钠可明显提高临床疗效,可以推广使用。【关键词】慢性阻塞性肺疾病;急性加重期;低分子肝素钠Lowmole
3、cularweightheparinsodiuminthetreatmentofacuteexacerbationofchronicobstructivepulmonarydiseaseHuangChunlan(Departmentofrespiration,theFifthPeople'sHospitalofChengduelderly,Sichuan,Chengdu,610000)【Abstract]Objective:Toinvestigatethelowmolecularweightheparininchronicobstructiv
4、epulmonarydiseasewithacuteexacerbation(AECOPD)application.Methods:from2011January-2012yearinDecembermycourtyardofelderlyhospitalizedintheDepartmentofrespirationof100casesofchronicobstructivepulmonarydiseasewithacuteexacerbationpatientsjandomlydividedintoobservationgroupandc
5、ontrolgroup,50patientsineachgroup・Thegroupof100casesofobstructivepulmonarydiseaseinacuteexacerbationperiodallpatientstookconventionaltreatment,theneedfornoninvasiveventilationatthesametime,alsoineludesthesugarcorticalhormone,bronchodilator,effectiveantibiotics,controlledoxy
6、gentherapy.Onthebasisoftheobservationgroupinthenavelsubcutaneousinjectionoflowmolecularweightheparinsodium,modelis6000U’oncedailyfortendays.Results:Afterthetreatment,50casesoftheobservationgroup40cases(80%),improvedin9cases(18%),invalidin1cases(2%),thetotalefficiencyof98%.5
7、0casesofthecontrolgroup30cases(60%),improvedin8cases(16%)」nvalidin12cases(24%),thetotalefficiencyof76%.Theapplicationofx2test(x2=424),thedifferencebetweenthetwogroupswassign讦icant(P<O05).Thecontrolgrouphadadversereactionsoccurredin6cases,thetreatmentgrouponly2patientsdev
8、elopedlocalcongestionintheinjectionprocess,nootheradversereactions.Conclusion:Chro